Treatment results of continuous intra-arterial CBDCA infusion chemotherapy in combination with radiation therapy for locally advanced tongue cancer.
OBJECTIVE
The objective of this study was to improve the treatment results for locally advanced tongue cancer. A combination of radiotherapy with continuous intra-arterial therapy using CBDCA was used.


METHODS
According to TNM staging (1997), 29 patients had stage III lesions and 11 patients had stage IV (M0) lesions. A catheter was inserted through the lingual artery in 26 patients, through the external carotid artery in 11 patients, and through the faciolingual trunk in 2 patients. CBDCA was continuously infused for 4 to 6 weeks. With IA chemotherapy, external irradiation (median dose: 46.8 Gy) was simultaneously performed, and 1 to 2 courses of systemic chemotherapy were performed in 19 patients before intra-arterial chemotherapy.


RESULTS
The 5-year local control rate was 65%. The 5-year OS rate was 39.5%. There were no clinically significant adverse side effects.


CONCLUSIONS
Continuous IA CBDCA and concurrent radiation therapy can be delivered safely with good efficacy for locally advanced carcinoma of the tongue.
Fuwa
Nobukazu
N
Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. nfuwa@aichi-cc.jp
Kodaira
Takeshi
T
Furutani
Kazuhisa
K
Tachibana
Hiroyuki
H
Nakamura
Tatsuya
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002342:Carotid Artery, External; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000633:toxicity; D006801:Humans; D007261:Infusions, Intra-Arterial; D007275:Injections, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000633:toxicity; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D014059:Tongue / Q000098:blood supply; D014062:Tongue Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
D009944:Organoplatinum Compounds; C053989:nedaplatin; D016190:Carboplatin; D005472:Fluorouracil